Supernus Pharmaceuticals, Inc.

LSE:0LB2 Stock Report

Market Cap: US$2.1b

Supernus Pharmaceuticals Past Earnings Performance

Past criteria checks 4/6

Supernus Pharmaceuticals's earnings have been declining at an average annual rate of -35.1%, while the Pharmaceuticals industry saw earnings declining at 5.2% annually. Revenues have been growing at an average rate of 9% per year. Supernus Pharmaceuticals's return on equity is 5.9%, and it has net margins of 9.2%.

Key information

-35.1%

Earnings growth rate

-35.7%

EPS growth rate

Pharmaceuticals Industry Growth14.1%
Revenue growth rate9.0%
Return on equity5.9%
Net Margin9.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Supernus Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

LSE:0LB2 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2465260335103
30 Jun 24630533697
31 Mar 24597-1633795
31 Dec 23608133692
30 Sep 236112632986
30 Jun 236344335983
31 Mar 236685237275
31 Dec 226676137775
30 Sep 226593840578
30 Jun 226305736578
31 Mar 226017333477
31 Dec 215805330590
30 Sep 215648225187
30 Jun 2157110023485
31 Mar 2155611121291
31 Dec 2052012720176
30 Sep 2047712917778
30 Jun 2042411816278
31 Mar 2040211615273
31 Dec 1939311315369
30 Sep 1940810616165
30 Jun 1940910516269
31 Mar 1940410316472
31 Dec 1840911115589
30 Sep 183819915276
30 Jun 183598715268
31 Mar 183357314759
31 Dec 173025713850
30 Sep 172765813347
30 Jun 1725310411842
31 Mar 172289710942
31 Dec 162159110643
30 Sep 161968410139
30 Jun 16179269840
31 Mar 16163189536
31 Dec 15147148929
30 Sep 15135118425
30 Jun 1511857821
31 Mar 1511257419
31 Dec 1493-117320
30 Sep 1472-377019
30 Jun 1450-596718
31 Mar 1421-896017

Quality Earnings: 0LB2 has high quality earnings.

Growing Profit Margin: 0LB2's current net profit margins (9.2%) are higher than last year (4.2%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0LB2's earnings have declined by 35.1% per year over the past 5 years.

Accelerating Growth: 0LB2's earnings growth over the past year (133%) exceeds its 5-year average (-35.1% per year).

Earnings vs Industry: 0LB2 earnings growth over the past year (133%) exceeded the Pharmaceuticals industry 9.5%.


Return on Equity

High ROE: 0LB2's Return on Equity (5.9%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 23:07
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Supernus Pharmaceuticals, Inc. is covered by 18 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Emily BodnarBerenberg
David BuckB. Riley Securities, Inc.
John TannerCantor Fitzgerald & Co.